Latest Biotech News

Researchers introduced an explainable AI framework aimed at improving recognition of intentional injury mortality, covering both suicide and homicide, reported in Scientific Reports. The approach...

CancerNetwork previewed which trial data may draw attention when the 2026 ASCO Annual Meeting opens. The pre-meeting embargo lift highlighted cost-effectiveness data from the phase 3 CHALLENGE...

Researchers unveiled a prognostic nomogram designed for children with aplastic anemia (AA) treated with cyclosporine monotherapy, aiming to address the unpredictable response to treatment. The...

A Nature Communications study reported deep profiling of skin remodeling in systemic sclerosis following immunotherapy, using cellular and molecular analyses to map changes in diseased tissue. The...

Researchers identified a role for the zinc finger protein ZNF274 in blocking lineage switching while also fueling CDK7 drug resistance in cancer models, according to a study described in the...

An Italian multicenter study reported real-world evidence that lumacaftor/ivacaftor is safe and effective in preschool-aged children with cystic fibrosis carrying relevant genotypes, including...

Researchers described a kidney-protective mechanism mediated by CD5L, reporting that the protein shields kidneys by reducing cellular oxidative stress. The study outlines how CD5L influences...

A study released a long-term comparative analysis of AAV9-mediated gene replacement therapies in murine spinal muscular atrophy (SMA) models. It compares engineered gene therapy versions over...

The FDA cleared Gilead’s hepatitis D therapy Hepcludex (bulevirtide) four years after the agency previously rejected the drug tied to manufacturing and distribution issues. The approval gives...

ASCO will highlight a wave of pancreatic cancer innovation beyond KRAS, with daraxonrasib’s new data expected to anchor attention. Abstract coverage also points to multiple mechanism classes,...

A phase 3 ENGOT-ENG-NSGO/GOG-3031/RUBY update showed durable disease control with dostarlimab plus chemotherapy in dMMR/MSI-H endometrial cancer. At a median follow-up of 55.6 months, 4-year...

The FDA approved datopotamab deruxtecan (Dato-DXd; Datroway) for unresectable or metastatic triple-negative breast cancer patients who are not candidates for PD-1/PD-L1 inhibitor therapy. The...

A University of Pennsylvania and Children’s Hospital of Philadelphia case study highlighted meaningful clinical benefits from an mRNA-based CRISPR base-editing approach in an infant with CPS1...

Parabilis moved to the public markets with an IPO filing a day after signing an up-to-$2.3 billion-plus Regeneron collaboration. The Helicon-based antibody-drug conjugate platform deal centers on...

US policy pressure is building around outbound capital flows into China biotech, with lawmakers urging restrictions. A GOP lawmaker asked the Trump administration to curb China biotech deals,...

Researchers unveiled a prognostic nomogram designed to predict early outcomes in childhood aplastic anemia for patients treated with cyclosporine monotherapy. The model targets a long-standing...

AbbVie began another round of layoffs tied to its Allergan footprint, issuing a WARN notice for 85 permanent job cuts at its Irvine, California site. The company framed the actions within its eye...

Cenevo launched an AI-enabled inventory search capability for its Mosaic connected-lab platform, designed to let scientists query labware and stored samples using natural language. The feature,...

The FDA cleared AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate Datroway for first-line treatment of triple-negative breast cancer (TNBC) when patients are not candidates...

The EMA’s Committee for Medicinal Products for Human Use recommended Boehringer Ingelheim’s nerandomilast, branded as Jascayd, as a replacement option as generic nintedanib (Ofev) approaches the...